Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ104MR)

This product GTTS-WQ104MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ104MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12699MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ7376MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ8417MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ4942MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ11415MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ13189MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ13587MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ7714MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW